Researchers at the University of Strathclyde have implemented powerful technology from NVIDIA which the institution claims will enable the use of AI to rapidly accelerate the process of manufacturing treatments
Academic researchers in Glasgow have installed a supercomputer to support the use of artificial intelligence in developing new medicines.
The University of Strathclyde has implemented an NVIDIA DGX H100 machine, which the institution described as would enable the next wave of AI research and development. Using autonomous robotic platforms driven by hybrid AI and physics-based models, it is hoped the technology can revolutionise drug development and manufacturing.
- NHS offered £21m fund to invest in AI-powered diagnostic tools
- AI will save lives of 22,000 cancer patients a year, prime minister announces
- Artificial intelligence to empower public services, says minister
The supercomputer will dramatically enhance computational capabilities, allowing for scientific exploration at unprecedented speed, according to the university. In the coming weeks, the university will launch a series of challenges to find applications that could use the DGX H100 to support pharmaceutical development and manufacturing.
“This investment demonstrates our commitment to drive the digital transformation of CMC (chemistry, manufacturing and control) processes for medicines development and manufacture,” said professor Alastair Florence. “This groundbreaking infrastructure will allow us to work with our partners to develop novel AI solutions that will help us to produce new medicines more quickly, more affordably and with greater resilience of supply.”
Professor Blair Johnston added: “From novel ChatGPT-like large language models for medicines manufacturing to real-time imaging applications deployed at the edge on our advanced manufacturing process lines, NVIDIA DGX H100 will allow us to advance research challenges previously beyond accessible computational capabilities. Working collaboratively with NVIDIA’s experts and pharma partners we are in a strong position to further accelerate the impact of [our] portfolio of industrial digital technology research on medicines development in the coming years.”